Navigation Links
Dyadic International Reports 2011 Second Quarter Financial Results
Date:8/4/2011

JUPITER, Fla., Aug. 4, 2011 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the quarter ended June 30, 2011. The financial information contained in this press release should be read in conjunction with the financial statements and related footnotes which have been posted on the OTC market website at www.otcmarkets.com/stock/DYAI/financials and on Dyadic's website at www.dyadic.com/wt/dyad/investors.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO)

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "The second quarter was highlighted by two important transactions. We opened the quarter with our first significant research collaboration in biopharmaceuticals with Sanofi Pasteur and EnGen Bio to leverage Dyadic's C1 technology to produce certain vaccines. We closed the quarter with a research, development and license agreement with a major player in the animal feed industry to use C1 to produce new animal feed products. These and other transactions show the benefits of providing integrated solutions to our partners and customers which include research, licensing and product offerings. Finally, we added to the value and protection of our products and technologies with the issuance of several new U.S. patents."

Second Quarter Highlights

  • Total revenue for the second quarter increased approximately 35% over the same period last year
  • Gross profit for the second quarter increased by 81% over the same period last year as a result of higher license fee revenue, improved product margins and further cost controls and operational efficiencies
  • Entered into a research and development collaboration with Sanofi Pasteur and EnGen Bio to use Dyadic's patented C1 technology for certain vaccine applications
  • Entered into a long-term research, development and license agreement with a major player in the animal feed industry to use Dyadic's patented C1 technology to develop, manufacture and commercialize animal feed products
  • Completed the final arbitration hearing in Dyadic's professional liability lawsuit against its former auditors
  • Received three new U.S. patents

  • Financial ResultsTotal revenue for the second quarter ended June 30, 2011 increased to approximately $3.0 million compared to approximately $2.2 million for the second quarter ended June 30, 2010. Total revenue for the six months ended June 30, 2011 increased to approximately $5.3 million compared to approximately $4.2 million for the six months ended June 30, 2010. The increase in total revenue for the three and six month periods ended June 30, 2011 as compared to the same periods ended June 30, 2010 was due to an increase in license fee revenue and, with respect to the six month comparison, also due to an increase in research and development revenue.

    Net product related revenue for the second quarter ended June 30, 2011 decreased to approximately $1.6 million compared to approximately $1.7 million for the second quarter ended June 30, 2010. Net product related revenue for the six months ended June 30, 2011 decreased to approximately $3.5 million from approximately $3.6 million for the same period a year ago. The decrease in net product related revenue was primarily due to a decline in sales of textile enzymes.

    Research and development revenue for the second quarter ended June 30, 2011 decreased to approximately $323,000 compared to approximately $465,000 for the second quarter ended June 30, 2010. Research and development revenue for the six months ended June 30, 2011 increased to approximately $814,000 compared to approximately $554,000 for the six months ended June 30, 2010.

    License fee revenue for the second quarter ended June 30, 2011 increased to approximately $1.0 million compared to no license fee revenue for the second quarter ended June 30, 2010. License fee revenue for the six months ended June 30, 2011 increased to approximately $1.0 million compared to approximately $32,000 for the six months ended June 30, 2010. The increases in license fee revenue for the three and six month periods ended June 30, 2011 compared to the same periods ended June 30, 2010 were due to a $1.0 million upfront license fee recognized in the second quarter of 2011 from a major player in the animal feed industry pursuant to the research, development and license agreement entered into between Dyadic and this commercial partner in June 2011.

    Net loss for the second quarter ended June 30, 2011 was approximately $736,000, or $(0.02) per basic and diluted share, compared to a net loss of approximately $1.4 million, or $(0.05) per basic and diluted share for the second quarter ended June 30, 2010. Net loss for the six months ended June 30, 2011 was approximately $2.2 million, or $(0.07) per basic and diluted share, compared to a net loss of approximately $2.5 million, or $(0.08) per basic and diluted share, for the six months ended June 30, 2010.

    At June 30, 2011, cash and cash equivalents were approximately $3.0 million compared to approximately $4.5 million at December 31, 2010. A significant portion of the decrease in cash since the end of last year was due to costs incurred by Dyadic in the completion of the arbitration portion of its professional liability lawsuit against its former auditors and outside counsel.

    Conference CallDyadic's second quarter 2011 financial results conference call is scheduled for 5:00 p.m. Eastern Time on Thursday, August 4, 2011. The conference call may be accessed by dialing 800-378-6902 (from the United States or Canada) or 913-312-0399 (from other countries) five to ten minutes prior to start time and providing the passcode 2428811. A replay of the conference call will be available on the Dyadic website (www.dyadic.com) shortly after the live event.

    About DyadicDyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries.

    Dyadic trades on the OTC Pink tier of the OTC market. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC market website (www.otcmarkets.com/stock/DYAI/quote).

    Cautionary Statement for Forward-Looking StatementsCertain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Six Months Ended June 30, Three Months Ended June 30, 2011201020112010Revenue: (Unaudited) (Unaudited) (Unaudited) (Unaudited) Product Related Revenue, Net

    $

    3,452,554

    $

    3,618,937$

    1,647,346

    $

    1,739,792License Fee Revenue1,017,00032,0001,017,000-Research and Development Revenue814,102553,575322,793465,340Total Revenue5,283,6564,204,5122,987,1392,205,132Cost of Goods Sold3,213,1533,090,9791,684,8271,485,650Gross Profit2,070,5031,113,5331,302,312719,482Expenses:General and Administrative3,012,3372,634,1421,327,7461,274,476Sales and Marketing 536,453472,596268,719245,863Research and Development 622,117648,634318,114362,595Foreign Currency Exchange Losses (Gains), Net(81,344)260,54312,690227,246Total Expenses4,089,5634,015,9151,927,2692,110,180(Loss) from Operations(2,019,060)(2,902,382)(624,957)(1,390,698)Other Income (Expense):Interest Income6,67536,0122,48414,741Interest Expense(226,737)(65,066)(113,731)(31,687)Gain on Reduction of Accrued Stockholder Litigation-410,000--Other-243-243Total Other Income (Expense)(220,062)381,189(111,247)(16,703)Net (Loss)

    $

    (2,239,122)

    $

    (2,521,193)$

    (736,204)

    $

    (1,407,401)Net (Loss) per Common ShareBasic

    $

    (0.07)

    $

    (0.08)$

    (0.02)

    $

    (0.05)Diluted

    $

    (0.07)

    $

    (0.08)$

    (0.02)

    $

    (0.05)Weighted Average Common Shares Used in Calculating Net (Loss) Per Share:Basic31,265,05430,906,70631,271,26930,985,745Diluted31,265,05430,906,70631,271,26930,985,745DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETSJune 30, 2011December 31, 2010ASSETS(Unaudited)Current Assets:Cash and Cash Equivalents

    $

    3,042,688$

    4,535,279Restricted Cash270,452247,082Accounts Receivable, Net1,627,0911,276,574Inventory, Net3,116,7942,782,433Prepaid Expenses and Other Current Assets423,482336,638Total Current Assets8,480,5079,178,006Fixed Assets, Net648,995719,161Intangible Assets, Net372,495310,978Other Assets16,93016,930$

    9,518,927$

    10,225,075LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts Payable

    $

    2,285,126$

    1,801,123Accrued Expenses641,245417,996Accrued Interest Payable  113,530146,230Deferred Research and Development Obligation150,369-Note Payable to Stockholder1,424,9411,424,941Income Taxes Payable168168Total Current Liabilities4,615,3793,790,458Convertible Subordinated Debt4,000,0004,000,0008,615,3797,790,458COMMITMENTS AND CONTINGENCIESStockholders’ Equity:Preferred Stock, $.0001 Par Value:Authorized Shares – 5,000,000; None Issued and Outstanding--Common stock, $.001 par value,Authorized Shares – 100,000,000; Issued and Outstanding  – 31,409,620 and 31,138,120, Respectively31,41031,138Additional Paid-in Capital77,807,12777,101,690Stock to be Issued2,344-Accumulated Deficit(76,937,333)(74,698,211)903,5482,434,617$

    9,518,927$

    10,225,075DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Six Months Ended  June 30, 2011 2010 (Unaudited) (Unaudited) Operating ActivitiesNet Income (Loss)

    $

    (2,239,122)$

    (2,521,193)Adjustments to Reconcile Net (Loss) to Net Cash (Used In) Operating Activities:Depreciation and Amortization of Fixed Assets138,151151,096Amortization of Intangible and Other Assets15,4027,068Reduction of Allowance for Doubtful Accounts(50,011)(132,030)Reduction of Inventory Reserve(75,389)(333,795)Compensation Expense on Stock Option Grants658,684425,032Stock Issued for Financial Services-63,000Gain on Reduction of Accrued Stockholder  Litigation-(410,000)Changes in Operating Assets and Liabilities:Accounts Receivable(300,506)(118,717)Inventory(258,972)399,751Prepaid Expenses and Other Current Assets(86,844)117,787Accounts Payable484,003(66,234)Accrued Expenses223,249(434,030)Accrued Interest Payable(32,700)(26,088)Accrued Stockholder Litigation-(1,500,000)Deferred Research and Development Obligation150,369-Income Taxes Payable-1,238Net Cash (Used In) Operating Activities(1,373,686)(4,377,115)Investing ActivitiesPurchases of Fixed Assets(76,919)(157,315)Cost of Patents(67,985)(6,284)Restricted Cash(23,370)45,589Net Cash (Used In) Investing Activities(168,274)(118,010)Financing ActivitiesProceeds from Stock Warrant Exercises15,00016,876Proceeds from Stock Option Exercises34,36922,801Net Cash Provided by Financing Activities49,36939,677Net (Decrease) in Cash and Cash Equivalents(1,492,591)(4,455,448)Cash and Cash Equivalents at Beginning of Period4,535,2798,419,934Cash and Cash Equivalents at End of Period

    $

    3,042,688$

    3,964,486Supplemental Cash Flow Information:Cash Paid for Interest

    $

    259,437$

    91,154
    '/>"/>

    SOURCE Dyadic International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Dyadic International Announces Date of Second Quarter 2011 Financial Results Release and Conference Call
    2. Dyadic International Enters Into Research and License Agreement With Major Player in the Animal Feed Industry
    3. Dyadic to Present at the World Congress on Industrial Biotechnology & Bioprocessing
    4. Dyadic Netherlands Enters Into R&D Collaboration With Sanofi Pasteur and EnGen Bio
    5. New U.S. Patent Issued to Dyadic International
    6. Dyadic International to Present at Advanced Biofuels Leadership Conference
    7. Dyadic International Introduces Advanced Biofuels Enzyme AlternaFuel® CMAX™ At World Biofuels Markets
    8. Dyadic International Reports 2010 Fiscal Year Financial Results
    9. Dyadic International Launches High Performance Enzyme for Pulp and Paper Industry Using New C1 Production Platform
    10. Dyadic International Reports 2010 Third Quarter Financial Results
    11. Dyadic International to Announce Third Quarter 2010 Financial Results and Hold Conference Call on November 15, 2010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
    (Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
    (Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
    (Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
    Breaking Biology Technology:
    (Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
    (Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
    (Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
    Breaking Biology News(10 mins):